High Peak Royalties Limited (ASX:HPR)

Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions AUD. Fiscal year is July - June.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 4, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Market Capitalization	13	17	14	15	9	13
Market Cap Growth	37.10%	24.07%	-7.14%	54.82%	-28.57%	-5.41%
Enterprise Value	13	17	14	16	10	15
Last Close Price	0.06	0.08	0.07	0.07	0.05	0.07
PE Ratio	-	-	27.56	-	-	-
PS Ratio	12.66	15.30	8.92	13.97	20.88	21.44
PB Ratio	1.43	1.82	1.44	1.64	1.06	1.30
P/TBV Ratio	34.24	39.69	42.54	-	-	-
P/FCF Ratio	-	42.46	21.17	48.01	-	-
P/OCF Ratio	75.66	42.46	21.17	48.01	-	-
EV/Sales Ratio	12.47	15.27	9.30	14.92	22.92	24.64
EV/EBITDA Ratio	70.05	58.51	15.12	33.97	-	-
EV/EBIT Ratio	-	-	23.00	108.04	-	-
EV/FCF Ratio	-	42.37	22.07	51.25	-	-
Debt / Equity Ratio	-	0.12	0.16	0.21	0.22	0.25
Debt / EBITDA Ratio	-	3.94	1.61	3.99	-	-
Debt / FCF Ratio	-	2.85	2.35	6.01	-	-
Asset Turnover	0.10	0.10	0.14	0.10	0.04	0.04
Quick Ratio	0.87	1.18	3.65	2.55	2.05	3.81
Current Ratio	1.98	1.21	3.81	2.61	2.13	3.81
Return on Equity (ROE)	-2.89%	-2.06%	5.36%	-8.51%	-13.57%	-10.44%
Return on Assets (ROA)	-0.88%	-0.22%	3.50%	0.83%	-2.58%	-1.14%
Return on Capital (ROIC)	-0.90%	-0.22%	3.54%	0.83%	-2.63%	-1.17%
Return on Capital Employed (ROCE)	-	-	5.80%	1.40%	-	-
Earnings Yield	-2.03%	-1.14%	3.63%	-5.19%	-13.73%	-8.57%
FCF Yield	-	2.35%	4.72%	2.08%	-5.05%	-1.61%
Buyback Yield / Dilution	0.28%	0.37%	-2.89%	-7.47%	-	-4.40%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.